

Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Gastrointestinal Cancer

A Clinical Investigator Think Tank

Select Publications

A phase III randomized, double-blind trial of chemoembolization with or without sorafenib in unresectable hepatocellular carcinoma (HCC) in patients with and without vascular invasion. NCT01004978

Arnold D et al. **Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).** *Proc ASCO 2012;Abstract CRA3503.*

Cartwright TH et al. **Effect of the 12-gene colon cancer assay results on treatment recommendations in patients with stage II colon cancer.** *Proc ASCO 2012;Abstract 3626.*

Corcoran RB et al. **BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212).** *Proc ASCO 2012;Abstract 3528.*

Demetri GD et al. **Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.** *Proc ASCO 2012;Abstract LBA10008.*

George S et al. **Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: A multicenter phase II trial.** *J Clin Oncol 2012;30(19):2401-7.*

Grothey A et al. **Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE).** *J Clin Oncol 2008;26(33):5326-34.*

Llovet JM et al. **Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial.** *Lancet 2002;359(9319):1734-9.*

Lo CM et al. **Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.** *Hepatology 2002;35(5):1164-71.*

Marrero JA et al. **Global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib (GIDEON) second interim analysis in more than 1,500 patients: Clinical findings in patients with liver dysfunction.** *Proc ASCO 2011;Abstract 4001.*

O'Connell MJ et al. **Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU+Ox).** *Proc ASCO 2012;Abstract 3512.*

Ross JS et al. **Use of next-generation sequencing (NGS) to detect a novel ALK fusion and a high frequency of other actionable alterations in colorectal cancer (CRC).** *Proc ASCO 2012;Abstract 3533.*

Van Cutsem E et al. **Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A biomarker evaluation from the AVAGAST randomized phase III trial.** *J Clin Oncol 2012;30(17):2119-27.*

Van Cutsem E et al. **Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC).** *Proc ASCO 2012;Abstract 3502.*

Van Cutsem E et al. **Intravenous (IF) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCC): Results of a multinational phase III trial (EFC10262-VELOUR).** *Proc WCGC 2011;Abstract O-0024.*